BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24375390)

  • 1. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
    Raymond E; García-Carbonero R; Wiedenmann B; Grande E; Pavel M
    Cancer Metastasis Rev; 2014 Mar; 33(1):367-72. PubMed ID: 24375390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
    Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
    Strosberg JR
    Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.
    Capdevila J; Meeker A; García-Carbonero R; Pietras K; Astudillo A; Casanovas O; Scarpa A
    Cancer Metastasis Rev; 2014 Mar; 33(1):345-51. PubMed ID: 24375391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
    Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
    Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.
    Oberg K; Casanovas O; Castaño JP; Chung D; Delle Fave G; Denèfle P; Harris P; Khan MS; Kulke MH; Scarpa A; Tang LH; Wiedenmann B
    Clin Cancer Res; 2013 Jun; 19(11):2842-9. PubMed ID: 23459719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
    Beyens M; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
    Endocr Relat Cancer; 2019 Mar; 26(3):R109-R130. PubMed ID: 32022503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Strosberg J; Goldman J; Costa F; Pavel M
    Front Horm Res; 2015; 44():239-47. PubMed ID: 26303716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Modlin I
    Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of targeted therapies in the management of neuroendocrine tumours.
    Verset G; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Verslype C; Van Laethem JL
    Acta Gastroenterol Belg; 2009; 72(1):59-62. PubMed ID: 19402374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors.
    Chen P; Wang Q; Xie J; Kwok HF
    Semin Cancer Biol; 2019 Oct; 58():80-89. PubMed ID: 31054326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S; Sablin MP; Dreyer C; Raymond E
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA; Kulke MH
    Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
    Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
    Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
    Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
    Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
    Iyer R; Phan AT; Boudreaux JP
    Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):1-24. PubMed ID: 28654022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
    Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
    Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.